https://ir.vikingtherapeutics.com/ https://ir.vikingtherapeutics.com/2026-06-24-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Novel-Amylin-Receptor-Agonist-VK3019-in-Healthy-Adults Wed, 24 Jun 2026 07:05:00 -0400 https://ir.vikingtherapeutics.com/2026-06-24-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Novel-Amylin-Receptor-Agonist-VK3019-in-Healthy-Adults https://ir.vikingtherapeutics.com/2026-06-11-Viking-Therapeutics-Announces-Appointment-of-Hubert-C-Chen,-M-D-,-as-Chief-Medical-Officer Thu, 11 Jun 2026 07:05:00 -0400 https://ir.vikingtherapeutics.com/2026-06-11-Viking-Therapeutics-Announces-Appointment-of-Hubert-C-Chen,-M-D-,-as-Chief-Medical-Officer https://ir.vikingtherapeutics.com/2026-05-21-Viking-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences Thu, 21 May 2026 07:05:00 -0400 https://ir.vikingtherapeutics.com/2026-05-21-Viking-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026 Tue, 12 May 2026 07:05:00 -0400 https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026 https://ir.vikingtherapeutics.com/2026-05-05-Viking-Therapeutics-Announces-Two-Poster-Presentations-at-European-Congress-on-Obesity-ECO-2026 Tue, 05 May 2026 07:05:00 -0400 https://ir.vikingtherapeutics.com/2026-05-05-Viking-Therapeutics-Announces-Two-Poster-Presentations-at-European-Congress-on-Obesity-ECO-2026